Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

636.34 -12.36 (-1.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 414,915
Open 640.84
Bid (Size) 625.00 (1)
Ask (Size) 636.34 (1)
Prev. Close 648.70
Today's Range 635.74 - 652.52
52wk Range 538.01 - 747.42
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amgen Moves to Dismiss Regeneron's Antitrust Case Regarding Cholesterol Drug
 
Via Benzinga
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace

Performance

YTD
+1.47%
+1.47%
1 Month
+8.46%
+8.46%
3 Month
-3.47%
-3.47%
6 Month
+0.86%
+0.86%
1 Year
-1.71%
-1.71%

More News

Read More
Kodiak's Eye Disease Candidate At Par With Regeneron's Eylea In Visual Acuity Gains
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
$100 Invested In This Stock 15 Years Ago Would Be Worth $3,300 Today
Via Benzinga
Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain
Via Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
Via Investor's Business Daily
Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
Via Benzinga
New Tensions Between The US And China Provoked Investors To Return To Safe-Haven Assets
Via Talk Markets
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Regeneron Pharmaceutical Beats Second-Quarter Views But Logs No Covid Sales
Via Investor's Business Daily
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Via Benzinga
7 Cathie Wood Stocks Trading at a Discount Right Now
Via InvestorPlace
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022
Via Benzinga
Meta Platforms To $250? Plus This Analyst Lowers Price Target On Microsoft
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Air Pollution is a Global Heart and Lung Health Concern
Via FinancialNewsMedia
Topics Climate Change Emissions Energy
Exposures Climate Fossil Fuels
Small Cap Biotech Stocks Are Trending Well
Via Talk Markets
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Via Benzinga
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Via Benzinga
What Are Whales Doing With Regeneron Pharmaceuticals
Via Benzinga
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.